SynbioTech reveals immune health probiotic at Probiota Americas 2026

Biotechnology company SynbioTech has launched Synmue, a clinically validated probiotic for immune aging — age-related decline of immune function, also known as immunosenescence, containing Lactiplantibacillus plantarum LP28. The company is showcasing the probiotic at the ongoing Probiota Americas 2026 (Jun 8–10) in Vancouver, Canada. 

With the launch, the company says it emerges in the immune aging category. The LP28 strain has completed a human trial, evaluating participants aged 50–75 who have a medical history of recurring upper respiratory tract infections.

SynbioTech says the findings demonstrate how the probiotic can help alleviate age-related immune decline, positioning it as a microbiome-based solution for immune resilience in older adults.

Addressing immune decline

The randomized double-blind placebo-controlled study, yet to be published, took place over 12 weeks and showed that the participants taking LP28 had an up to 48% increase in natural killer (NK) cell cytotoxic activity compared to the baseline. 

The study found favorable changes in immune-related biomarkers.NK cells serve as a “front-line defense mechanism” by identifying and eliminating virus-infected and abnormal cells, and they are a key component of the natural immune system.

“By supporting NK cell function, LP28 may help address one of the key biological mechanisms associated with age-related immune decline. The clinical result strengthens Synmue as a microbiome-based solution for partners focused on long-term immune resilience,” says the company.

Additionally, the study found favorable changes in immune-related biomarkers, as it observed reduced inflammatory burden (C-reactive protein) and improved immune regulation (interleukin-12). 

During the 12-week intervention period, the participants who consumed LP28 also showed a lower occurrence of common colds. The company says these findings suggest the improvements in NK cell activity and immune-regulation have the potential to offer benefits for healthy aging. 

The product focuses on immune aging and long-term resilience, rather than seasonal wellness, notes SynbioTech. 

Tapping into a growing market

The company stresses that there are currently few nutritional solutions targeting immunosenescence, which may lead to increased infections, reduced psychological resilience, and slower recovery.

At the event, the company will present how microbiome modulation can drive functional outcomes “beyond gut health.”“Synmue was developed to address a critical dimension of healthy aging that has often been overlooked,” says Sean Yang, chief operating officer of SynbioTech. “As people live longer, maintaining immune resilience becomes increasingly important for preserving health span.”

The launch builds on the company’s healthy aging portfolio, as it focuses on immune resilience through NK cell activation. It adds to the company’s sports probiotic TWK10, created to enhance exercise endurance.

“Together, TWK10 and Synmue reflect SynbioTech’s expanding vision for healthy aging, supporting both muscle and immune resilience through clinically validated microbiome science,” says SynbioTech.

At Probiota Americas, the company is presenting how microbiome modulation can drive functional outcomes “beyond gut health.”

“Healthy aging is multidimensional,” says Yang. “Preserving muscle function and immune resilience are both essential to extending health span. Through Synmue and TWK10, we are building science-backed microbiome solutions designed to help people age stronger, stay resilient, and live better.”